Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title: LFD Repo		rt for 12 th March – 8 th Apr 2022	Page 1 of 16

DOCUMENT VERIFICATION

Prior to using this document, the user is responsible for verifying that the revision and effective date are current.

REVISION HISTORY

Rev.	Effective Date	Changes Made to Document
1	22/04/2022	First Issue

1. Content

- 1. Content
- 2. Introduction
- 3. Reference documents
- 4. Standards and guidelines
- 5. Methodology
- 6. Findings /Results
 - 6.1 In-House manufacturing inspection at Biotime
 - 6.2 Receiving inspection Intertek Testing in the UK
 - 6.3 Product complaints & Qualtrics Survey Reports
 - 6.4 Complaints Trending
 - 6.5 Qualtrics Survey (User Experience)
 - 6.6 Product Management (Useability Studies)
 - 6.7 Real World Performance Monitoring
 - 6.8 Post Market Performance Follow Up
 - 6.9 Variants of Concern (VOC)
 - 6.10 CAPA
 - 6.11 SCAR Supplier Corrective Action Report
 - 6.12 Risk Management
 - 6.13 Literature Review & State of the Art (SOTA)
- 7. Conclusion & Risk-Benefit Determination
- 8. Recommended Actions
- 9. Attachments
- 10. Author

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title:	LFD Repo	rt for 12 th March – 8 th Apr 2022	Page 2 of 16

2. Introduction

The LFD kit is an IVD medical device intended by DHSC to be used *in vitro* for the examination of combined throat and nasal specimens derived from the human body solely for the purpose of providing information concerning Covid-19 infection. The device is classified as a **IVD Device for self-testing.**

The PSR report outlines, analyses and reports on the activities that were undertaken by DHSC to ensure the performance and safety of the DHSC LFD during its life cycle in line with the PMS Procedure and PMS Plan.

This was performed thorough the continuous data generation and assessment of the DHSC LFD performance post market and aims to discuss (through presentation of data) the questions below:

a) Were there any new hazard or hazardous situation(s) identified for the DHSC LFD's or has the risk acceptability changed?

b) Has any misuse of the DHSC LFDs occurred?

c) Do the DHSC LFD's still meet the user's needs after medium/long term clinical use?

d) Do users experience any usability issues?

e) Are there any recurring quality issues DHSC LFD's and can significant increasing/decreasing trends be identified for DHSC LFD' inadequate performance?

3. Reference documents

Doc ID	Doc name	Revision
QM-01	Quality manual	1
QOP-25	Post- Market Surveillance (PMS)	3
	Procedure	
PMS-0001	PMS Plan for the DHSC COVID-	2
	19 LFD device (3 and 7 kit)	
RMF-001	Risk Management File	5
QP08-F02	LFD Hazard Traceability Matrix	1

Table 1: Reference to internal documentation

4. Standards and guidelines

ISO 9001:2000 Quality management systems – Requirements.

• ISO 13485:2016 Medical devices - Quality management systems - Requirements for regulatory purposes.

ISO 14971:2019 Medical devices -- Application of risk management to medical devices.

5. Methodology

- Data is gathered as per the PMS Plan referenced in Table 1.
- All inputs are stored in a centralised LFD PSR location on SharePoint
- All inputs are submitted via the relevant departments as per the PMS plan.

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title: LFD Repor		t for 12 th March – 8 th Apr 2022	Page 3 of 16

6. Findings /Results

6.1 In-House manufacturing inspection at Biotime

There were no inspections carried out between the reporting period of 12 Mar 2022 and 08 Apr 2022 following conclusion of QC of the previous contract on 30/01/2022. No further Innova product has been procured during this reporting window.

(Refer to Attachment 5.1)

6.2 Receiving inspection - Intertek Testing in the UK

A total of 5,880 samples underwent validation from the 12/03/2022 until 08/04/2022, from 56 lots. From these samples, there were no red flags recorded.

(Refer to Attachment 5.2)

6.3 Product complaints & Qualtrics Survey Reports

• The number of kits distributed in this reporting period is ~ 89 million which is decrease of ~21 million over the previous reporting month.

• A total of 58 complaints were received from Qualtrics, MHRA Yellow card and 119 Call in this reporting period and were discussed at the weekly incident review meetings and weekly Patient safety panel meetings.

• Fifty-seven of those complaints were defined as non-reportable as per Med Dev 12.1 Rev 8.

• One of the 57 complaints was defined as a reportable complaint when discussed at the weekly patient safety panel (MORE ref: 2022/004/004/601/002).

• A total of 619 user reports were received from the Qualtrics survey in relation to the DHSC LFD during this reporting window.

• No Lot specific trend was identified in this reporting window.

• Further information on the trending categories, number of complaints, reportability/non-reportability, investigations and further actions is documented in Table 2.

(Refer to attachment 02.1)

Department of Health &		Periodic Summary Report	Doc. Number PSR-016 Revision
Social Care	э		1
Title:	LFD Repor	rt for 12 th March – 8 th Apr 2022	Page 4 of 16

	Qualtrics and Yellow card complaints investigation					
Trending category	Number of complaints	Reportability	Investigation	Further actions		
Missing components	282	Not reportable	There was no trend observed for any particular batch.	Most of the complaints were back dated yellow card received from MHRA. Corrective actions were taken as part of the previous SCAR raised with the supplier. The complaints received are for the batches which were delivered before the corrective action were implemented. However, the list of these complaints has been passed to the supplier for their visibility.		
Damaged Item	60	Not reportable	There was no trend observed for any particular batch.	No further action. Complaints will be monitored for trending purposes		
Faulty test results	54	Not reportable	There was no trend observed for any particular batch.	Most of the complaints were back dated yellow card received from MHRA. Corrective actions were taken as part of the previous SCAR raised with the supplier. The complaints received are for the batches which were delivered before the corrective action were implemented. However, the list of these complaints has been passed to the supplier for their visibility.		
Faulty items	57	Not reportable	There was no trend observed for any particular batch.	No further action. Complaints will be monitored for trending purposes		
Patient injury	3	Not reportable	There was no trend observed for any particular batch.	Not enough information to investigate and no contact details to follow up.		
Allergic reactions	6	5 Not reportable & 1 Reportable (MORE ref: 2022/004/004/601/002)	This was decided to be not reportable by the clinical team in the incident review meeting	No further action. Complaints will be monitored for trending purposes		
Empty extraction buffer	20	Not reportable	There was no trend observed for any particular batch.	No further action. Complaints will be monitored for trending purposes		
Wrong media volume	72	Not reportable	There was no trend observed for any particular batch.	No further action. Complaints will be monitored for trending purposes		
Bar code/QR code issues	65	Not reportable	Complaints forwarded to NHS digital team for investigation	Complaints were due to user error wherein the user has typed incorrect barcode resulting into rejected and duplicated QR complaints		

Table 2: Summary of reportability/non-reportability for all complaints

*Not reportable: these complaints did not meet the reportability criteria set out in MED DEV 2.12 rev 8 vigilance standard and hence were decided to be non-reportable. MED DEV 2.12 rev 8 vigilance Guidance to support discussions at Incident Review Meetings & Patient Safety Panel:

- Question A "Has an event occurred etc."
- Question B "Is DHSC device cause of incident"
- Question C "Has the event led to death or serious deterioration in health"

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title: LFD Repo		rt for 12 th March – 8 th Apr 2022	Page 5 of 16

6.4 Complaints Trending

Current trending categories analysed through the Qualtrics data are grouped into three main categories:

- 1) Material: this includes trending categories: Missing item, Damaged Item, Faulty item, Contaminated Item, QR code issues, Empty Buffer Solution Sachet, Insufficient Buffer Solution. From the graph (see Figure 1), the alert level is triggered twice during this reporting period. Upon investigation, it is noted that most of the complaints were back dated MHRA Yellow Cards which inevitably triggered the alert level when logged. Some reports were related to missing items which were fed back at the monthly supplier management meeting and resulted in a SCAR being raised (Ref: SCAR-2022-025).
- 2) Faulty Test Results: No sub-categories exist within this category of complaints. From the graph (see Figure 2) the alert level is triggered twice on investigating and similar to the material complaints, the spike was attributed to back dated MHRA yellow cards. No further batch related issues were observed.
- 3) Harm & Allergy: this includes complaints from Patient Injury and Allergic reactions as sub-categories. From the graph (see Figure 3), Harm-allergy complaints for this reporting period Alert level has triggered. However, it is not clear if the complaints received during this period are for this period as out of 5 harm-allergy complaints, 3 came from MHRA yellow card with no incident date provided. Also, during this period, UKHSA received an influx of backdated yellow card reports, it is likely that these 3 reports are also backdated. However, investigation was carried out on these 5 complaints, and it was found that for 3 complaints were reported with no batch number and no reporter details were available for investigation and follow up. The remaining 2 complaints were related to gag reflex, which is known issue and the IFU is updated to cover this.





Figure 1: Material complaints weekly trending






Figure 2: Faulty results complaint weekly trending




Figure 3: Harm-Allergy complaints weekly trending

(Refer to Attachment 2.2)

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title:	LFD Repo	rt for 12 th March – 8 th Apr 2022	Page 7 of 16

6.5 Qualtrics Survey (User Experience)

A total of 1379 user responses were received during this reporting window of 12^{th} March -8^{th} Apr 2022 for all LFD products for which the DHSC is either the legal manufacturer or distributor.

62.5% of these responses were related to the DHSC LFD Products (**highlighted in green in Attachment 2.3**). 717 users completed 100% of the survey in an average time of 7.91 minutes. This is an improvement on the last reporting period where 55 additional users completed 100% of the survey.

A series of questions relating to the user's overall experience can be seen in **Attachment 2.3**. Satisfaction rates were predominantly above 80% for most queries relating to the useability of the LFD products, except for:

- 1) **Reporting of results (Understanding of IFU):** 65.11% satisfaction rate which is a reduction on the last reporting period by 9.28%.
- 2) **Reporting of results (Difficulty of process):** 58.25% satisfaction rate which is a reduction of 9.8% since the last reporting period.

On-going product improvements are supported at the procurement stage by the LFD Product Management team and information on user experience from the Qualtrics survey is to be shared with the team for continual improvement. As discussed in previous reporting periods, actions have already been instigated at the next round of invitation to tender (ITT). Further information has been retained in this PSR from the previous reporting period and referenced in **Section 6.6**.

(Refer to Attachment 2.3)

6.6 Product Management (Useability Studies)

The LFD Product Team are involved in a Three-Stage process aimed at continuously improving the useability of LFD products sourced by DHSC and supplied to the end users (see Figure 4).

The team have carried out useability research activities with 2000 users through a mixture of surveys and one to one interview. The purpose of this research is to understand (from the user's perspective) what improvements can be made to the LFD product supplied.




Figure 4: LFD Product Management Teams Core Process

Findings from these useability studies feed into improvements in the procurement exercises (Invitation to Tender ITT).

Further information on some of the findings and actions were shared in the previous report and have therefore been omitted from this submission.

No further updates or planned studies are planned from the LFD Product Management team as sufficient data has been collected for the current range of LFD's. Any future studies planned will be discussed in the PSR report.

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title: LFD Repor		t for 12 th March – 8 th Apr 2022	Page 9 of 16

6.7 Real World Performance Monitoring

The Real-World Performance Monitoring Team carry out routine performance of device and service performance using real-world data generated within NHS Test & Trace covering all services and devices.

Below are summaries for the Void rates, confirmatory PCR rates, variant analysis, and the number of positives (i.e., positivity rates), for the reporting period 12th Mar 2022 – 08th Apr 2022.

Key metrics	What this metric tells us	Performance expectation given current population prevalence level of disease	Conclusion	Trend data					
Void rate	Measuring void rates provides insights into how users interpret results.		The void rate of 0.11% performs according to expectations.	Reporting Period end	Void rate	Positivity rate	Conf PCR count	Conf PCR rate	Expected con range
	Measuring void rates at a site level can	the site-level void rate should not be significantly		18/06/21	0.12%	0.40%	19,851	88.1%	40%-53%
	be used as an indicator of batch performance.	different from the 1.2% void rate Lower CI (as outlined in the technical document for Innova 3&7 self-test).	d	02/07/21	0.12%	0.84%	45,403	89.7%	64%-77%
				16/07/21	0.12%	1.61%	89,939	91.6%	79%-87%
Confirmatory PCR	provides an assessment of false below 70% and positive rates. By reviewing this at a service team and site level, it provides assurance as to the reliance which can are expected to	Services / sites are flagged if the conf PCR Rate is below 70% and the observed conf PCR Rate is lower than the Expected PCR Conf Rate Lower Est. Expected		30/07/21	0.13%	1.62%	70,509	91.2%	79%-88%
rate				11/08/21	0.13%	1.64%	38,788	91.89%	79%-87%
		performance is based on prevalence as Conf PCR rates		27/08/21	0.12%	1.71%	43,214	93.27%	80%-88%
		are expected to decrease in line with decreasing prevalence, and vice versa.		10/09/21	0.11%	1.37%	43,901	91.81%	77%-85%
				24/09/21	0.11%	1.36%	40,670	89.82%	76%-85%
Variant analysis	rates to be investigated. Measuring the number of, and relative	Comparing the relative proportion of strain detections	s Out of 24.746 conf PCRs in the	08/10/21	0.11%	1.56%	59,567	83.96%	79.0-86.9%
Y an arrest an arrests	Proportion of SARS-COV-2 strains detected via asymptomatic LFD testing, confirmatory PCR and sequencing. This is compared with proportion of strain cases detected in	 Comparing the relative proportion or strain detections measures whether UFDs are adequately detecting the spread of strains. It also allows to mitigate changes in sequencing coverage. 	the reported period for strains, 9,418	22/10/21	0.11%	1.94%	51,841	90.75%	82.5-89.3%
				05/11/21	0.12%	1.63%	45,114	93.39%	79.7-87.4%
				19/11/21	0.12%	1.48%	38,907	92.26%	77.8-86.1%
	the symptomatic and asymptomatic			03/12/21	0.13%	1.49%	37,425	91.53%	76.8-85.4%
	population.			17/12/21	0.14%	1.76%	46,176	91.39%	80.7-88.1%
				31/12/21	0.15%	4.10%	94,924	95.27%	91.5-95.0%
Number of positives (incl. positivity rate)	Measuring positivity provides an understanding into the number of	Given prevalence at a certain time period, a site is expected to have stable and consistent positivity rates	512,146 LFD positives were detected. The positivity rate of	14/01/22	0.11%	4.74%	103,201	92.56%	93.1-96.0%
(men braunard, race)	cases that are being detected. It also	The positivity rate changes in line with prevalence.	13.44% for the reporting period	28/01/22	0.12%	7.38%	47,967	91.35%	95.7-97.5%
	allows to quantify the number of positive cases identified via		reflects the incremental change in the number of positives detected.	11/02/22	0.11%	6.85%	35,658	91.01%	96.5-97.3%
	asymptomatic testing.			25/02/22	0.10%	4.92%	18,597	91.7%	94.9 - 96.1%
				11/03/22	0.10%	7.67%	24,746	95.9%	96.6 - 97.4%
				25/03/22	0.11%				

Table 1: Trend data of key metrics in all reporting periods

RWPM Report DHSC Self-Test 12/03/2022 - 25/03/2022 4

Figure 5: DHSC 3/7 self-test summary Period 12-Feb-2022 to 25-Mar-2022

						Tren	d data		
Key metrics	What this metric tells us	Performance expectation given current population prevalence level of disease	Conclusion	Reporting Period end	Void rate	Positivity	Conf PCR	Conf PCR	Expected co range
Void rate	Measuring void rates provides insights	Based on previous service evaluations analysis, it was established that the expected performance level for	The void rate of 0.10% performs according to expectations.	18/06/21	0.12%	0.40%	19,851	88.1%	40%-53%
Measuring void rates at a site level can the site-level void rate should n be used as an indicator of batch different from the 1.2% void rat performance. In the technical document for in	the site-level void rate should not be significantly		02/07/21	0.12%	0.84%	45,403	89.7%	64%-77%	
	different from the 1.2% void rate Lower CI (as outlined in the technical document for Innova 3&7 self-test).	8	16/07/21	0.12%	1.61%	89,939	91.6%	79%-87%	
				30/07/21	0.13%	1.62%	70,509	91.2%	79%-88%
rate	provides an assessment of false be positive rates. By reviewing this at a service team and site level, it provides pe assurance as to the reliance which can are	Services / sites are flagged if the conf PCR Rate is	The confirmatory PCR rate of 95.5% is above the 70% threshold yet below the Lower Est. of the expected performance range	11/08/21	0.13%	1.64%	38,788	91.89%	79%-87%
		below 20% and the observed conf PCR Rate is lower than the Expected PCR Conf Rate Lower Est. Expected performance is based on prevalence as Conf PCR rates are expected to decrease in line with decreasing prevalence, and vice versa.		27/08/21	0.12%	1.71%	43,214	93.27%	80%-88%
				10/09/21	0.11%	1.37%	43,901	91.81%	77%-85%
				24/09/21	0.11%	1.36%	40,670	89.82%	76%-85%
	allows the source of high false positive rates to be investigated.			08/10/21	0.11%	1.56%	\$9,567	83.96%	79.0-86.99
Variant analysis	rates to be investigated. Measuring the number of, and relative	Comparing the relative proportion of strain detections	Out of 40.572 conf PCRs in the	22/10/21	0.11%	1.94%	51,841	90.75%	82.5-89.39
vanant analysis	proportion of SARS-CoV-2 strains detected via asymptomatic LFD testing, confirmatory PCR and	measures whether LFDs are adequately detecting the	ately detecting the reported period for strains, 8,914	05/11/21	0.12%	1.63%	45,114	93.39%	79.7-87.49
		spread of strains. It also allows to mitigate changes in sequencing coverage.		19/11/21	0.12%	1.48%	38,907	92.26%	77.8-86.19
	sequencing. This is compared with proportion of strain cases detected in	active of the second		03/12/21	0.13%	1.49%	37,425	91.53%	76.8-85.49
	the symptomatic and asymptomatic			17/12/21	0.14%	1.76%	46,176	91.39%	80.7-88.19
	population.			31/12/21	0.15%	4.10%	94,924	95.27%	91.5-95.09
				14/01/22	0.11%	4.74%	103,201	92.56%	93.1-96.09
Number of positives	Measuring positivity provides an understanding into the number of	Given prevalence at a certain time period, a site is	402,182 LFD positives were	28/01/22	0.12%	7.38%	47,967	91.35%	95.7-97.5%
(incl. positivity rate)	cases that are being detected. It also	expected to have stable and consistent positivity rates The positivity rate changes in line with prevalence.	detected. The positivity rate of 13.36% for the reporting period	11/02/22	0.11%	6.85%	35,658	91.01%	96.5-97.39
	allows to quantify the number of positive cases identified via		reflects the incremental change in the number of positives detected.	25/02/22	0.10%	4.92%	18,597	91.7%	94.9 - 96.1
	asymptomatic testing.			11/03/22	0.10%	7.67%	24,746	95.9%	96.6 - 97.4
				25/03/22	0.11%	13.44%	40,572	96.2%	98.2 - 98.6
				08/04/22	0.10%	13.36%	17,099	95.5%	98.1 - 98.5

Figure 6: DHSC 3/7 self-test summary Period 26-Mar-2022 to 08-Mar-2022

(Refer to Attachments 3.1 & 3.2)

Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1
Title:	LFD Repo	rt for 12 th March – 8 th Apr 2022	Page 10 of 16

6.8 Post Market Performance Follow Up

DHSC has implemented a series of ongoing evaluations. The objective of these evaluations is to determine whether lateral flow device (LFD) performance seen in pre-deployment evaluations are achieved when deployed by the testing service and to ensure that these continue to be suitable for use in services offered by NHS Test and Trace.

The intention is that PMPF studies are carried out on a 6-month cadence to allow for recruitment of patients, compilation and analysis of results and completion of the final report.

Report 2 is expected to have been delivered to the MHRA on 14th Apr 2022. At the time of writing this PSR, the report was not available for inclusion. A summary will be provided in the next report.

(Refer to Attachment 07)

2000 Department		Periodic Summary Report	Doc. Number PSR-016
of Health & Social Care		Periodic Summary Report	Revision
			1
Title: LFD Report for 12 th March – 8 th Apr 2022		Page 11 of 16	

6.9 Variants of Concern (VOC)

The Variant of Concern Assurance Group (VOC) within the UKHSA are responsible for continuous monitoring of SARS-COV-2 variants. No new updates were received in time for this reporting window.

A meeting has been scheduled with the Variant of Concern Assurance Group (VOC) to discuss the monthly VOC input. An update will be available in the next reporting period.

6.10 CAPA

- Refer to Table 3 for a CAPA Status Overview
- Table 4 for List of open CAPA's and current progress and due dates.

CAPA Status	No
VOE	01
Open	01

Table 3: CAPA Status Overview

No	CAPA No	Start Date	Source	Problem statement	Status/ progress	Due date	Reason for extension if overdue
26	CAPA- 21- 06- 0039	26- Nov- 21	PMS Activities	CAPA raised due to a spike in LFD complaints taking them over the acceptable threshold	Complete pending VOE	VOE due 1 st July 2022	N/A
27	CAPA- 22- 01- 0041	05- Jan- 2022	PMS Activities	CAPA raised due to batch of SureScreen kits failing Intertek validation.	Open	30-Apr-2022	N/A

Table 4: List of open CAPA's, Status & Due date

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016
		Periodic Summary Report	Revision
			1
Title:	LFD Repor	rt for 12 th March – 8 th Apr 2022	Page 12 of 16

6.11 SCAR - Supplier Corrective Action Report

No new SCARs were raised by DHSC to Innova for this reporting period. It is important to note that no new EUA stock will be ordered from Innova. Any actions from existing SCARs will not be realised as all stock is already received by UKHSA. SCARs are being raised to support the supplier to continuously improve processes.

SCAR No.	Start	Description	Fault	Initial	Formal Response	Status
	Date		Detected	Response Date	Due Date	
SCAR-2022-018	08-Feb- 2022	This SCAR has been raised as a summary of the complaints received from end- users/patients relating to missing items within LFD kits kitted by Innova, covering the period of Dec 2021 & and Jan 2022.	Missing Component	10- Feb -2022	08-Mar-2022	Closed
SCAR-2022-025	04- Mar- 2022	This SCAR has been raised as a summary of the complaints received from end- users/patients relating to missing items within LFD kits kitted by Innova, covering the period of February 2022.	Missing component	7- Mar- 2022	01-Apr-2022	Closed

Table 5: SCAR Overview

6.12 Risk Management

LFD Risk management File (RMF) was updated to RMF-0001 Revision 5 and HTM Hazard traceability Matrix Rev5 *(Refer to Attachment 04)*. The RMF updated to new template for compliance with ISO 14971:2019

No new Hazards were identified during this reporting period as part of the continual monitoring through post-market surveillance activities.

Department of Health & Social Care		Doc. Number PSR-016 Revision 1
Title: LFD Report for 12 th March – 8 th Apr 2022		Page 13 of 16

6.13 Literature Review & State of the Art (SOTA)

In collaboration with an external consultancy, DHSC has developed a Literature Search Protocol. The intention of the literature search is to review the continued clinical safety and effectiveness of the Lateral Flow Device kit when used for the intended purpose. Furthermore, the MedBoard platform is utilized to obtain current data on incidents, Field Safety Corrective Actions (FSCAa), etc. reported to or by regulatory agencies internationally.

The literature search & SOTA search is carried out monthly in line with the PSR reporting schedule and utilizes multiple electronic search databases (e.g., PubMed, Embase & Medboard) as highlighted in the protocol. It is worth highlighting that due to the frequency and timing of the LFD PSR reports, it is not practical nor feasible to provide a detailed analysis and conclusions of findings from the literature search report. However, the literature searches will be continuously reviewed with the support of PHCO for on-going performance evaluation and separately, a high-level summary is provided in the monthly PSR report.

The March update was conducted 06 Apr 2022. No new articles were retrieved from neither the SOTA or safety and performance search.

(Refer to Attachment 06)

Department of Health & Social Care		Periodic Summary Report	Doc. Number PSR-016 Revision 1	
Title:	LFD Repo	rt for 12 th March – 8 th Apr 2022	Page 14 of 16	

7. Conclusion & Risk-Benefit Determination

The DHSC LFD test is intended to detect the presence of coronavirus (Covid-19) antigen in humans to enable the spread of the virus to be reduced in the community. The overall purpose of post-market surveillance activities is to ensure that the device continues to meet its intended purpose.

Questions posed in the Post Market Surveillance plan (PMS-001) and at the beginning of this report have been addressed in **Table 6** and summarised in this section.

It is noted that performance of the device demonstrated a Void Rate of **0.11%** for the period between 12th Mar 2022 to 25th Apr 2022 and 0.10% for the period between 26th Mar 2022 to 08th Apr 2022, which performs according to expectations and is below the threshold of **1.2%**.

The confirmatory PCR rate of **96.2%** between the period of 12^{th} Mar -25^{th} Mar 2022 and **95.5%** between the period of 26^{th} Mar 2022 and 08^{th} Apr 2022 which are above expected performance and provides assurance of positive LFDs confirmed by matched positive PCRs.

No new Hazards were identified during this reporting period as part of the continual monitoring through postmarket surveillance activities. Hazards identified in the previous reporting period were assessed and there was no change in the risk acceptability policy evident.

DHSC has not instigated a re-call nor issued any Field Safety Corrective Action Notices during this reporting period.

No new literature was found and no new Medboard SOTA literature was identified in Section 6.3 for this reporting period.

Based on the information discussed in this periodic summary report, the DHSC maintain the position that the benefits of use of Lateral Flow Devices continue to outweigh the risks identified in the risk management plan, these include:

- a) Early indication of possible infection with Covid-19 while still asymptomatic
- b) Prevention of spread of Covid-19 virus
- c) Prevention of the need for unnecessary self-isolation/travel restriction therefore improving patient/user quality of life.
- d) Widespread PCR testing is operationally unfeasible

Department of Health & Social Care		Periodic Summany Report	Doc. Number PSR-016
		renould Summary Report	Revision
			1
Title: LFD Report for 12 th March – 8 th Apr 2022		Page 15 of 16	

Question	Answer	Comments	Evidence
a) Were there any new hazard or hazardous situation(s) identified for the DHSC LFD's or has the risk acceptability changed?	No	No new hazards identified in this reporting period.	Section 6.12
b) Has any misuse of the DHSC LFDs occurred?	No	No formal complaints or reports in Qualtrics received to indicate the DHSC LFD was misused.	Section 6.3
c) Do the DHSC LFD's still meet the user's needs after medium/long term clinical use?	Yes	On-going real-world performance monitoring indicates void rates below expected threshold and confirmatory PCR tests in line with expectations.	Section 6.7 Section 6.8
d) Do users experience any usability issues?	No	Satisfaction rates are above 70% with regards to useability of the devices. Any minor issues identified are feeding into continuous improvement activities at the procurement stage.	Section 6.5 Section 6.6
e) Are there any recurring quality issues DHSC LFD's and can significant increasing/decreasing trends be identified for DHSC LFD' inadequate performance?	No	Issues relating to missing items were observed. A SCAR has already been raised against Innova/Biotime. Immediate containment action not deemed necessary as the risk on patient safety is minimal. Any improvements by Innova will not be realised as all products are received by UKHSA.	Section 6.4 Section 6.11

Table 6: Questions posed by PMS-001 Plan for DHSC LFD Products

No emerging issues or safety signals identified. As result of the PMS activities analysed/discussed in this report the PMS Team advice is to continue distributing the current EUA cleared product.

Department of Health &		Periodic Summary Report	Doc. Number PSR-016
Social Care			Revision
			1
Title: LFD Report for 12 th March – 8 th Apr 2022		Page 16 of 16	

8. Recommended Actions

No	Added	Action	Responsible Name	Due Date	Status
N/A	N/A	N/A	N/A	N/A	N/A

9. Attachments

Attachment 01: PMS-0001, PMS Plan for the DHSC Covit-19 LFD Devices (3 and 7 kit) Rev2, 29-July-2021 Attachment 02: DHSC PSR – Complaints & Qualtrics data (Attachments 2.1 – 2.3)

Attachment 03: RWPM Innova 3s and 7s

Attachment 04: QP08-F02 LFD Hazard Traceability Matrix v.01 Issued 22.12.2021

Attachment 05: Inbound Freight Data (Attachments 5.1 & 5.2)

Attachment 06: Literature Search Report - Lateral Flow Device 202204 withoutpapers

10. Author

	Job Title	Name	Email
Compiled by	Post Market Surveillance Manager		